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The cytochrome P450 mixed function oxidase enzymes play a major role in the metabolism of important
endogenous substrates as well as in the biotransformation of xenobiotics. The liver P450 system is the
most active in metabolism of exogenous substrates. This review brieﬂy describes the liver P450 (CYP)
mixed function oxidase system with respect to its enzymatic components and functions. Electron
transfer by the NADPH-P450 oxidoreductase is required for reduction of the heme of P450, necessary for
binding of molecular oxygen. Binding of substrates to P450 produce substrate binding spectra. The P450
catalytic cycle is complex and rate-limiting steps are not clear. Many types of chemical reactions can be
catalyzed by P450 enzymes, making this family among the most diverse catalysts known. There are
multiple forms of P450s arranged into families based on structural homology. The major drug metabo-
lizing CYPs are discussed with respect to typical substrates, inducers and inhibitors and their poly-
morphic forms. The composition of CYPs in humans varies considerably among individuals because of
sex and age differences, the inﬂuence of diet, liver disease, presence of potential inducers and/or in-
hibitors. Because of such factors and CYP polymorphisms, and overlapping drug speciﬁcity, there is a
large variability in the content and composition of P450 enzymes among individuals. This can result in
large variations in drug metabolism by humans and often can contribute to drug–drug interactions and
adverse drug reactions. Because of many of the above factors, especially CYP polymorphisms, there has
been much interest in personalized medicine especially with respect to which CYPs and which of their
polymorphic forms are present in order to attempt to determine what drug therapy and what dosage
would reﬂect the best therapeutic strategy in treating individual patients.
& 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The cytochrome P450 mixed function oxidase system plays a
major role in the metabolism of important endogenous substrates
such as in cholesterol biosynthesis and cholesterol conversion to
bile acids, formation of steroid hormones, androgens and estro-
gens, metabolism of vitamin D3 to the active 1,25-dihydrox-
yvitamin D3, omega hydroxylation of fatty acids, as well as bio-
transformation of exogenous xenobiotics. The biological effec-
tiveness and the potential toxicity of many drugs are strongly in-
ﬂuenced by their metabolism, much of which is accomplished by
P450-dependent monoxygenase systems. The wide array of che-
mical reactions performed by P450 makes this enzyme one of the
most versatile catalysts known. The liver, lung and skin micro-
somal P450s in particular are important in converting lipophilic
xenobiotics including drugs, insecticides, carcinogens, food.V. This is an open access article uadditives, and environmental pollutants to more polar compounds
which are easier to excrete. Intestinal CYPs, especially CYP3A4,
may be very important in promoting ﬁrst pass metabolism of
many drugs. Since many of these compounds, lose their activity or
potency after being metabolized to polar and excretable metabo-
lites, P450 was considered to be important as a cellular detox-
iﬁcation system. However, with certain compounds although the
parent xenobiotic is not toxic, metabolism by the P450 system can
generate reactive intermediates which are highly toxic e.g. CCL4,
nitrosamines and acetaminophen.
The term P450 designates a broad family of heme-containing
proteins found in bacteria, yeast, plants, invertebrates and verte-
brates. About 150 forms of P450 have been identiﬁed and a no-
menclature based on structural homology, largely deduced from
the corresponding cDNAs is used to classify these multiple forms
of P450 [1]. The nomenclature is based on evolutionary relation-
ships between CYP450 enzymes and not on similarity in substrate
proﬁles because of the overlapping substrate proﬁles of many CYPnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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strate at the same or even at different sites [2]. Many in vitro
studies using isolated microsomal fractions or intact hepatocytes
or cell lines have provided critical and basic information on drug
metabolism by CYPs despite the relative short term limitations of
such systems including lack of conjugation and other cytosolic
enzymes, loss of CYPs in culture, limited number of liver functions
expressed, lower levels of CYPs compared to in vivo. Studies to
improve such in vitro systems in order to be more reﬂective of the
in vivo state are an important research front.
Several of the contributions to the common theme series in
Redox Biology entitled “Role of CYP2E1 and Oxidative/Nitrosative
stress in the Hepatotoxic Actions of Alcohol” discuss the P450
enzyme CYP2E1. The goal of this brief overview is to summarize
the molecular mechanisms of the cytochrome P450 microsomal
drug oxidation system and perhaps be helpful as an educational
tool analogous to the Graphical Review by Dr. B. Kalyanaraman on
“Oxidants, Antioxidants and Disease Mechanisms” published in
Redox Biology [3].Cytochrome P450 General characteristics
The presence of a carbon monoxide-binding pigment in rat li-
ver microsomes was initially reported in 1958 [4,5]. The oxidized
and reduced spectrum of one member of the cytochrome P450
family of enzymes, CYP2E1, is shown in Fig. 1. The pigment, when
reduced, displayed a maximal absorbance at a wavelength ofFig. 1. Spectral characteristics of cytochrome P450. A: Absolute spectra of CYP2E1 pur
CYP2E1 in 0.1 M KPi, pH 7.4 buffer, 20% glycerol, 0.1 mM EDTA, 0.2% Emulgen 911 and
except for the omission of the CYP2E1. The scanned spectra were: oxidized CYP2E1 (so
bound reduced CYP2E1 (dashed line - - - -). B: The CO-CYP2E1 difference spectrum. Di
cuvettes. The sample cuvette was saturated with CO and spectra recorded over the ind450 nm when binding carbon monoxide and was called P (pig-
ment)-450. Spectral evidence revealed that P450 was a heme-
containing protein [6] and P450 plus cytochrome b5 accounted for
most of the hemoproteins found in liver microsomes. The content
of cytochrome P450 (nmol/mg microsomal protein) can be calcu-
lated from the ferrous carbon monoxide P450 versus ferrous P450
difference spectrum as described in detail in [7]. Cytochrome P450
was subsequently shown to function as the oxygen-activating
oxidase associated with microsomal oxygenation reactions such as
steroid C-21 hydroxylation, xenobiotic hydroxylation and oxida-
tive dealkylations [8,9]. Elevated activity of the microsomal mixed
function oxidase system after in vivo administration of certain
drugs was shown to be related to cytochrome P450 and its in-
ducibility [10]. CYPs are b-type cytochromes, containing proto-
porphyrin IX as the prosthetic group.
Cytochrome P450 is present in various vertebrates, in-
vertebrates and plants. In mammals, P450, while present at
highest levels in microsomes from liver (where it plays a major
role in detoxiﬁcation reactions) is also present in microsomes from
kidney, small intestine, lungs, adrenal cortex, skin, brain, testis,
placenta and other tissues [9]. Mitochondria, especially from liver
and endocrine tissue, contain P450. The nuclear envelope and
plasma membranes contain low amounts of P450 [11,12]. In plants,
P450s are involved in the synthesis of lignins and alkaloids.
Most P450s are made up of about 400–500 amino acids with
molecular weights of about 50,000 Da. About half of the amino
acids are non-polar. While earlier studies proposed P450 to be
buried in the membrane, it is now recognized that much of theiﬁed from pyrazole-treated rats [101]. The sample cuvette contained 0.39 nmol of
0.5% sodium cholate in a ﬁnal volume of 1 ml. The reference cuvette was identical
lid line); dithionite reduced CYP2E1 (dot/dashed lines -.-.-.-.-.); carbon monoxide-
thionite-reduced CYP2E1 (0.39 nmol/ml) was present in the sample and reference
icated wavelengths.
Fig. 2. Cartoon of the membrane topography of cytochrome P450 and of NADPH-cytochrome P450 reductase. Electrons for the reduction of molecular oxygen are provided
by the reductant/cofactor NADPH which is generated by the pentose phosphate pathway or mitochondrial transhydrogenase, and transferred via NADPH-cytochrome P450
reductase to the heme of cytochrome P450. Both the NADPH-P450 reductase and P450 are microsomal membrane associated, large parts of these enzymes protrude into the
cytosol and are attached to the membrane via their amino terminus.
Fig. 3. Substrate binding spectra to CYP2E1. CYP2E1 and various concentrations of the
CYP2E1 ligands DMSO (14–364mM) or pyrazole (6–51 mM) were added and the
spectrum was recorded over the indicated wavelengths until no further changes were
observed. A CO-CYP2E1 binding spectrum is shown by the solid lines with a peak at
451 nm. DMSO produces a type II substrate binding spectrumwith CYP2E1 with a peak
at 419 nm and trough at 386 nm. Pyrazole also produces a type II binding spectrumwith
a peak at 425 nm and trough at 390 nm. A Lineweaver–Burk plot of the concentration
dependence was linear (insert) and the spectral dissociation constants were calculated
to be 21 mM for DMSO and 0.04 mM for pyrazole. Results are from Ref. [101].
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terminus to the microsomal membrane (Fig. 2). Similarly, the
NADPH-cytochrome P450 reductase (discussed below) also largely
sticks out of the membrane (Fig. 2). The axial ligand for the heme
iron is a cysteine residue which is well conserved through evolu-
tion near the carboxy terminus of the protein and attaches the
heme to the protein. The sixth coordination position of the iron
may be water or be empty in the oxidized state and oxygen or
carbon monoxide in the reduced state. The addition of a substrate
may displace the water with subsequent effects on the redox po-
tential of the heme. The oxidation reduction potential as de-
termined by titrations with redox dyes is very low, with a mid-
point potential of about 0.34 to 0.40 V. Agents that react with
sulfhydryl groups or disrupt hydrophobic interactions convert
P450 to an inactive form called P420, based on the absorption
maximum of the ferrous P420–carbon monoxide complex. Con-
version of P450 to P420 usually results in loss of substrate-induced
spectral changes discussed below.
Substrates may change the optical properties of P450, so called
substrate binding spectra [13,14]. The substrate binding may pro-
mote the high spin state of the P450 with an absorption maximum
at about 390 nm and a trough at about 420 nm (Type I substrate
binding spectrum) or promote transition to the low spin state with
an absorption maximum at about 417 nm and a trough at about
390 nm (Type II substrate binding spectrum) [13,14]. Fig. 3 shows
the binding spectra when increasing concentrations of DMSO or
the chemical pyrazole, known ligands for CYP2E1, are added to
purify CYP2E1. Type II binding spectra were produced. The inset of
Fig. 3 shows a Lineweaver–Burk plot of these data in order to
calculate the spectral dissociation constants for DMSO (21 mM) or
pyrazole (0.04 mM) binding to CYP2E1. The substrate binding
spectra of ligands for cytochrome P450 can be intensiﬁed after
induction of the speciﬁc CYP which interacts with the ligands. For
example, CYP2E1 was induced by chronic ethanol feeding and
microsomes from the ethanol-fed rats and the dextrose-pair fed
controls were incubated with pyrazole or 4-methylpyrazole [15].
The magnitude of the Type II binding spectrum was intensiﬁed
with the microsomes from the ethanol-fed rats and the afﬁnity for
pyrazole and 4-methylpyrazole, as determined from Hanes–Wolf
plots was elevated by ethanol treatment in association with a 3–5
folds increase in CYP2E1 content [15].Electron transfer to P450
Reducing equivalents from either NADH or NADPH are required
for P450 to activate molecular oxygen for subsequent mixed
Fig. 4. Electron transfer to cytochrome P450. NADPH is the preferred reductant for microsomal cytochrome P450. Electrons are passed from NADPH to the FAD cofactor of
the reductase which passes electrons to the FMN cofactor which than reduces the heme of P450. NADH is less effective than NADPH in reacting with the P450 reductase and
reducing P450. NADH effectively reduces the FAD component of the NADH-cytochrome b5 reductase which then reduces the second major heme enzyme in microsomes,
cytochrome b5. The system is important in fatty acid desaturation. However, it is not very efﬁcient, relative to the NADPH cytochrome P450 reductase in reducing the heme of
cytochrome P450. For reduction of mitochondrial cytochrome P450, iron sulfur proteins are required. The scheme depicts the roles of the FAD adrenodoxin reductase in
reducing the adrenodoxin iron–sulfur protein and subsequently, mitochondrial cytochrome P450.
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constituted from its molecular components was the 11 β-hydro-
xylase system of adrenal cortex mitochondria [16]. This system
was separated into a P450-containing membrane fraction and a
soluble NADPH-P450 reductase activity; the latter was further
resolved into an iron–sulfur protein and a ﬂavoprotein reductase
and the sequence
NADPH- ﬂavoprotein-iron sulfur protein-P450
was established [16]. A similar electron transfer pathway that used
NADH in place of NADPH was found for the camphor hydroxylase
system of the bacterium Pseudomonas putida [17]. Iron sulfur
proteins, while required for mitochondrial P450 electron reduction
are not involved in microsomal P450 electron reduction. The
microsomal drug metabolism system contains two major compo-
nents, the P450 and its reductant, the NADPH cytochrome P450
reductase [18] (Fig. 4). The mammalian microsomal cytochrome
P450 reductase contains 2 mol of ﬂavin, one FAD and one FMN, per
mol of reductase enzyme. The activity of NADPH-cytochrome P450
reductase can be assayed via its ability to reduce other acceptors,
usually ferric cytochrome c, following the increase in absorbance
at a wavelength of 550 nm as described in [7]. The reductase is
also active in providing reducing equivalents for microsomal heme
oxygenase activity. A recent review of the roles of the reductase in
physiology, pharmacology and toxicology can be found in [19].
Cytochrome P450s use molecular oxygen and reducing
equivalents to catalyze the monooxygenation of a variety of sub-
strates (RH) by the following general reaction:
RHþNAD(P)HþO2-ROHþNAD(P)þH2O
This reaction is referred to as a mixed function oxidase reaction
since one atom of oxygen is incorporated into the substrate (hydro-
xylation) while the other is reduced to water. P450s cannot directly
accept electrons from NADH or NADPH, therefore a cytochrome P450
reductase containing FMN and FAD is necessary to reduce the heme
of microsomal P450. For mitochondrial P450 reduction, a FAD con-
taining reductase and an iron–sulfur protein are necessary (Fig. 4). For
microsomal P450 reduction, NADPH rather then NADH is the pre-
ferred reductant for transferring reducing equivalents to the NADPH-
P450 reductase and then to cytochrome P450. NADH generally isabout 10% as effective as NADPH in promoting microsomal P450 ac-
tivity. NADH transfers electrons to the FAD containing ﬂavoprotein
NADH-cytochrome b5 reductase which reduces cytochrome b5
(Fig. 4). Experiments with inhibitors, antibodies and reconstitution
experiments with puriﬁed enzymes have provided clear evidence for
the major role of the NADPH-P450 reductase in reducing P450. The
reduced b5 may to some extent reduce P450. In some cases, NADH
may further increase NADPH-dependent P450 catalytic activity by
providing the second electron required for the P450 catalytic cycle
(described below). The NADH/ NADH cytochrome b5 system is nor-
mally involved in transferring electrons to the cyanide sensitive factor
required for fatty acid desaturation. A summary of the electron
transfer pathways involved in P450 catalyzed reactions [9,20,21] is
shown in Fig. 4.
Rat liver microsomes contain about 0.05 nmol/mg protein of
NADPH-cytochrome P450 reductase and 0.05 nmol/mg of NADH-cy-
tochrome b5 reductase, about 0.5 nmol/mg of cytochrome b5 and
about 0.5–1 nmol P450/mg protein. Therefore, the molar ratios of the
two cytochromes are about an order of magnitude greater than that
of the corresponding reductase. Molecular weights of cytochrome b5,
the NADH reductase and the NADPH reductase are about 17,000,
40,000 and 80,000 Da, respectively [9,22], while that for cytochrome
P450s are about 46–60,000 Da depending on the molecular form.
Fig. 5 shows the absorption spectrum of oxidized cytochrome b5 and
after its reduction with dithionite. The two reductases and b5 are
typical integral membrane proteins that are amphipathic, attaching to
the microsomal membrane via a short hydrophobic region and con-
taining a large hydrophilic catalytic domain which protrudes into the
cytosol of the cell and thus are accessible to reducing equivalents. As
mentioned above, most of the P450 also protrudes out of the mi-
crosomal membrane, being attached to the membrane at its amino
terminus. The amino terminus is believed to anchor P450 to the en-
doplasmic reticulum and to act as a microsomal membrane inser-
tional signal [23,24]. For example, removal of the amino terminus of
CYP2E1 promotes its translocation to the mitochondria [25].Phase 1 (I) and phase 2 (II) drug metabolism
The general reaction catalyzed by cytochrome P450s is to
oxidize lipophilic substrates to more hydrophilic products e.g.
Fig. 5. Absorption spectrum of microsomal cytochrome b5. Solid line is the spec-
trum for oxidized cytochrome b5 with a peak at 412 nm. The dashed line is the
absorption spectrum after reduction with dithionite, with a peak at 423 nm. Re-
duced cytochrome b5 does not bind CO.
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generally involves oxidation, reduction and hydrolysis reactions
and is catalyzed by a number of enzymes, the most important
being CYPs [26,27]. The phase 2 metabolic reactions catalyze
conjugation reactions of lipophilic compounds with endogenous
cofactors such as glucuronic acid, sulfate, glutathione or acetate
(acetyl CoA). Phase 2 conjugation of a drug can occur in the ab-
sence of phase 1 metabolism. The hydroxylated product produced
from phase 1 reactions can also be conjugated by conjugation
enzymes to more hydrophilic products, easier to excrete. Often,
phases 1 and 2 pathways work together to help in the removal of
the xenobiotic. An example is shown in Fig. 6 for the conversion of
benzene to phenyl sulfate. Among the conjugation enzymes (and
the conjugated product) are those promoting glucuronidation, the
UDP-glucuronyl transferases (R-Glucuronide), sulfation by sulfo-
transferases (R-Sulfate), acetylation, by N-acetyl transferases
(acetylated R), methylation by methyltransferases (R-CH3) and glu-
tathionylation by various glutathione transferases (R-SG) (Fig. 6).
The conjugation reactions are not only important for excretion
of the drug but also help to minimize drug toxicity. For example,
the widely used drug acetaminophen (N-acetyl-p-aminophenol) isFig. 6. Phase 2 conjunormally metabolized largely by glucuronidation and sulfation to
form nontoxic acetaminophen-conjugated products. A small
amount of acetaminophen can be oxidized by CYPs, especially
CYP2E1 to a reactive N-acetyl-p-quinone imine (NAPQI), which
alkylates proteins, especially mitochondrial proteins. This reactive,
toxic metabolite can be removed by conjugation with GSH. Acet-
aminophen toxicity is magniﬁed when conjugation with glu-
curonic acid or sulfate is compromised or after intake of very high
levels of acetaminophen which saturate the conjugation pathways
thereby increasing formation of the reactive NAPQI. NAPQI toxicity
is magniﬁed especially when glutathione conjugation is impaired
because of depletion of hepatic levels of GSH e.g. by alcohol,
thereby causing accumulation of NAPQI [28,29]. These reactions
are summarized in Fig. 7.Catalytic activity of cytochrome P450
There is tremendous diversity in the reactions catalyzed by
cytochrome P450, which may be one of the most versatile cata-
lysts known [30–33]. The reactions catalyzed by P450 may be
broadly categorized as: metabolism of endogenous constituents
including steroids, cholesterol, bile acids, vitamins, fatty acids, and
eicosanoids; conversion of lipophilic exogenous xenobiotics into
more polar products which can be conjugated to more soluble
products for detoxiﬁcation and removal from the body and me-
tabolism of certain xenobiotics such as CCL4, acetaminophen,
benzene, halothane and nitrosamines into more reactive products
that are toxic or carcinogenic. Conversion of drugs into toxic pro-
ducts as a consequence of metabolism by the microsomal mixed-
function oxidase system is a major reason for failure of many drugs
in pre and post clinical trials [34–36].
Oxidative reactions that are catalyzed by P450 enzymes have
been characterized and discussed by Guengerich and colleagues
[34,37,38] and representative ones are shown in Fig. 8 – aliphatic
hydroxylations, aromatic hydroxylation, epoxidation, N-deal-
kylation, O-dealkylation, S-dealkylation, N-hydroxylation, oxida-
tive deamination, oxidative denitrosation, oxidative dehalogena-
tion, oxidative desulfuration, sulfoxidation. P450 can also catalyze
reductive reactions under anaerobic or hypoxic conditions e.g.
nitro reduction of nitropyrenes, azo reduction (aminoazobenzene),gation enzymes.
Fig. 7. Phases 1 and 2 acetaminophen metabolism. Acetaminophen consumed in “normal” amounts can be removed by direct conjugation by sulfotransferase or glucur-
onidation by glucuronyl transferases to produce acetaminophen sulfate or acetaminophen glucuronide, which are excreted. When present at high levels, the conjugation
reactions become limiting and acetaminophen can be oxidized by several CYPS, especially CYP2E1 to form the reactive N-acetyl-p-benzoquinone imine. The quinone imine
can be removed by conjugation with GSH. However, when formed in high amounts at high levels of acetaminophen or when GSH levels are low because of liver disease or
alcohol intake, the reactive quinone imine forms covalent adducts with proteins, especially mitochondrial proteins. Impairment of mitochondrial bioenergetics leads to liver
necrosis. Acetaminophen toxicity is one of the leading causes of liver damage and emergency room visits.
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The latter plays a critical role in the use of CCL4 in toxicological
reactions to cause lipid peroxidation followed by liver damage,
ﬁbrosis and cirrhosis. In general, some of these reactions may be
carried out by one form of P450 while others may be carried out
by many forms. Some substrates may be oxidized by one form of
P450 at a low concentration but another form at a high con-
centration e.g. low levels of the cancer-inducing N,N-ni-
trosodimetylamine are demethylated by CYP2E1 (low Km de-
methylase) whereas higher concentrations are demethylated by
several P450s including CYPs 2B1 and 2B2 [39]. The structural
features necessary for a substrate to be oxidized by a particular
P450 are still not clear despite much investigation.The cytochrome P450 catalytic cycle
A general mechanism for microsomal cytochrome P450 cata-
lysis as described in Refs. [20,32–35] is shown in Fig. 9. Substrates
for P450s have Km values ranging from nM to mM. Binding of the
substrate to the oxidized ferric P450 (RH, step 1) may or may not
be rapid (depending on the P450 and the substrate) and may or
may not change the oxidation/reduction potential of the heme.
Binding of substrate to the heme of P450 leads to displacement of
water as the 6th ligand to the heme iron, changing the spin state of
the iron from low spin to high spin [14]. A change to a more po-
sitive redox potential would accelerate acceptance of electrons
from the NADPH reductase to reduce the heme from the ferric to
the ferrous heme (step 2). Molecular oxygen binds rapidly to the
substrate–ferrous P450 (step 3) to form the ternary P450-oxygen–
substrate complex (oxy-P450). Carbon monoxide competesfavorably with oxygen for binding to ferrous P450 thereby in-
hibiting P450 activity and providing the basis for detecting and
quantifying P450 in biological systems at 450 nm as the ferrous
P450– carbon monoxide complex [7]. The ferrous O2 complex can
display a resonance structure in which an electron from the fer-
rous is transferred to the O2 to produce the ferric–O2 complex.
Decay of this complex produces the ferric-P450–substrate com-
plex with release of superoxide anion radical, the focus of pro-
duction of normally small amounts of reactive oxygen inter-
mediates during the P450 cycle [40–42]. The decay of the P450–
substrate-superoxide complex is dependent on the nature of the
substrate, the form of P450 and the efﬁcacy of input of a second
electron to reduce the oxy ferrous P450 to the peroxy P450 com-
plex (substrate–ferrous P450-superoxide or substrate–ferric P450-
peroxide) (step 4). Decay of the latter produces H2O2 plus sub-
strate–ferric P450. The second electron may come from the
NADPH P450 reductase (like the ﬁrst electron) or it may come
from reduced cytochrome b5 [43,44]. The ability of cytochrome b5
to provide the second electron to reduce oxy-P450 and continue
the P450 cycle may explain the ability of b5 to stimulate (or in-
hibit) certain P450-dependent reactions [45]. Subsequent steps of
the cycle (steps 5–8) are not very clear but it is believed that
heterolytic cleavage of the O–O bond of peroxy P450 yields H2O
and a ferryl type oxidant (step 5). The ferryl like oxidant abstracts
a hydrogen from the substrate (RH) to produce a substrate radical
(Rd, step 6) and the bound equivalent of a hydroxyl radical (FeOH).
Rapid oxygen rebound to the substrate radical (radical re-
combination) yields the hydroxylated substrate product (step 7)
and regenerates the ferric P450 (step 8) [20,30,32–35].
With such a complex overall reaction pathway, it is difﬁcult to
ascertain what step(s) is rate limiting for P450-catalyzed reactions.
Fig. 8. General type of reactions catalyzed by cytochrome P450 enzymes. Other reactions, not shown, include aryl migration, ring contraction, ring formation, ring coupling,
dimer formation, group migration (shown in Ref. [33]).
Fig. 9. The CYP catalytic cycle. Please see text for discussion. Oxygen surrogates
such as hydroperoxides can replace NADPH, oxygen and the NADPH-cytochrome
P450 reductase in promoting certain CYP-catalyzed reactions by forming active
oxygenated–CYP complexes. For example:
RHþFe3þ (CYP)-RH-Fe3þ (CYP)
RH-Fe3þ (CYP)þXOOH-XOHþRd (Fe–OH)3þ (CYP)
R∙ (Fe–OH)3þ (CYP)-ROH-Fe3þ (CYP)-ROHþFe3þ CYP.
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steps may be rate-limiting. Input of the ﬁrst and especially the
second electron may at times be limiting. Substrate may facilitate
entry of the ﬁrst electron [46]. Carbon–hydrogen bond breakage ofthe substrate to produce the substrate radical may be limiting
based upon kinetic isotope effects with deuterated substrates [47].
Cytochrome b5 may stimulate, have no effect or inhibit. Decay of
the oxygenated P450 complex may vary among different forms of
P450 and thereby limit the monoxygenase reaction e.g. CYP2E1
appears to be a “loosely coupled” form of P450 associated with
elevated rates of production of superoxide and H2O2 [48,49]. De-
pending on the form of P450, there may be a 1:1:1 stoichiometry
between the amount of oxygen consumed, the amount of product
formed and the amount of NADPH used. In some cases, the stoi-
chiometry is poor unless other products of molecular oxygen re-
duction such as superoxide or peroxide or especially water are
taken into account. For example, with CYP2E1, a considerable
amount of the oxygen and NADPH consumed produces water [48].
Excellent reviews on the P450 catalytic cycle can be found in Refs.
[42,50,51].
So-called oxygen surrogates may replace NADPH, oxygen and
the reductase in promoting certain P450-catalyzed reactions.
Agents such as hydroperoxides (e.g. cumene hydroperoxide) can
react directly with P450 to produce an active oxygenated P450
complex that can oxygenate certain substrates [52]. Usually these
reactions are much more rapid than the NADPH-dependent reac-
tions indicating that electron transfer from the reductase to P450
is a limiting step in the overall P450 mechanism.Multiple forms of cytochrome P450s
The very broad substrate speciﬁcity, the differential effect of
inducers and inhibitors on P450 reactions, the multiple bands on
Table 2
Human liver drug metabolizing CYPS-content and % drug metabolism.
CYP Percent drug metabolized Percent of total human liver P450
1A2 10–12 5
2A6 3–5 2
2B6 3–5 2–4
2C8/9 15 11
2C19 7–9 5
2D6 30 20–30
2E1 3–5 2–4
3A4/5 35–40 40–45
A.I. Cederbaum / Redox Biology 4 (2015) 60–73 67SDS-gels, and multiphasic Lineweaver–Burk plots, all pointed to
the presence of many forms of P450 enzymes. This was conﬁrmed
by puriﬁcations of different P450s and by molecular biology. It is
now recognized that more than 150 separate forms of P450 exist.
The human genome project has identiﬁed 57 human genes coding
for the various P450 enzymes (http://drnelson.utmem.edu/Cyto
chromeP450.html) OR (http://drnelson.uthsc.edu/human.P450.ta
ble.html).
Numerous names were given to these different forms as they
were puriﬁed or identiﬁed and the older literature can be con-
fusing on nomenclature. A systematic nomenclature is now used
which assigns proteins into families and subfamilies based on their
amino acid similarities. Proteins within a family exhibit greater
than 40% homology while those with at least 55% homology are in
the same subfamily. The written notation is an Arabic number
designating the gene family followed by a letter for the subfamily
and an Arabic number for individual genes within a subfamily.
Thus CYP1A1 and CYP1A2 are two individual P450s in family
1 subfamily A.
One way of categorizing the multiple forms of human CYPs is
by the substrates they oxidized (Table 1, derived from Ref. [37]).
About one half of the human CYPs metabolize endogenous sub-
strates such as steroids, bile acids, fatty acids, eicosanoids and
vitamins. The other 50% function to metabolize xenobiotics [37]. In
general, members of the CYPs 1, 2 and 3 families are the most
important in catalyzing oxidation of exogenous drugs and are
generally present in highest amounts in human liver (Table 2,
derived from Ref 26,31,34,37 53). In the P450 reactions with drugs,
90–95% of clinical drugs are metabolized by 5 of the 57 human
CYPs: 1A2, 2C9, 2C19, 2D6 and 3A4 [54]. CYPs 3A4/5 oxidize about
40% of the drugs used clinically. CYPs 2C, 2D and 1A also meta-
bolize many clinically-used drugs. Together, CYPs 2A6, 2B6 and
2E1 oxidize less than 10% of clinical drugs (Table 2). Recently,
Rendic and Guengerich [55] reported on the contributions of hu-
man P450 enzymes in carcinogen metabolism. Their Fig. 2B of Ref
55 showed the fraction of P450 activation reactions for carcino-
gens attributed to individual human P450 enzymes as follows:
CYP1A1, 20%; CYP1A2, 17%; CYP1B1, 11%; CYP2A6, 8%; CYP2E1, 11%;
CYP3A4, 10%; others 23%. Members of the CYP4 family are active in
metabolizing fatty acids, especially arachidonic acid while CYPs 7,
11, 17 and 19 are most important in steroid metabolism (Table 1).
CYPs 24A1, 27B1 and 26B1 play a role in vitamin D and retinoic
acid metabolism, respectively (Table 1). Approaches that are used
to predict or estimate the contribution of an individual CYP to the
metabolism of a drug include comparison of rates measured withTable 1
Classiﬁcation of CYPS based on the substrates they oxidize.
Sterols Xenobiotics Fatty acids Eicosanoids Vitamins
1B1 1A1 2J2 4F2 2R1
7A1 1A2 4A11 4F3 24A1
7B1 2A6 4B1 4F8 26A1
8B1 2A13 4F12 5A1 26B1
11A1 2B6 8A1 26C1
11B1 2C8 27B1
11B2 2C9
17A1 2C18
19A1 2C19
21A2 2D6
27A1 2E1
39A1 2F1
46A1 3A4
51A1 3A5
3A7
Modiﬁed from Refs. [33,34,37]. Other CYPs such as CYP2A7, 2S1, 2U1, 2W1, 3A43,
4A22, 4F11, 4F22 4V2, 4X1, 4Z1, 20A1, 27C1 are referred to as orphan CYPs as
speciﬁc substrates have not been identiﬁed [37].recombinant P450s, correlation of the catalytic activity of the drug
with marker activities of individual CYPs, use of speciﬁc selective
inhibitors or antibodies against the CYP and evaluation of the drug
metabolism remaining activity, and determining the effect of a
speciﬁc CYP inducer on the drug oxidation activity [54].
Table 3 summarizes some representative substrates for the
major human liver drug metabolizing CYPs. Table 4 summarizes
representative inhibitors and inducers (discussed below) for the
major human liver drug metabolizing CYPs.
Differences in expression of speciﬁc CYPs and active CYPs in
humans can be due to differences in gene regulation and the
presence of genetic polymorphisms. CYPs 2A6, 2C9, 2C19 and 2D6
in particular display polymorphisms [56,57]. As an example, a
listing of many cytochrome P450 genes and their polymorphisms
can be found in Table 1 of Ref. [53] and in http://www.imm.ki.se/
CYPalleles/. The effect of the polymorphism may include formation
of an inactive CYP enzyme, CYP gene deletion, formation of an
unstable CYP which rapidly degrades, formation of a CYP with
lower afﬁnity for the cytochrome P450 reductase, formation of a
CYP with altered substrate speciﬁcity or altered substrate afﬁnity,
or even increased CYP activity due to a gene duplication [58]. An
example of such effects for polymorphisms of CYP2D6 is shown in
Table 5 (derived from [58,59]).Induction of cytochrome P450s
The ability of certain xenobiotics to elevate their own meta-
bolism has long been known and the mechanism proposed was
that the agent increased the content of the P450 responsible for its
metabolism. Table 4 lists classical inducers of liver microsomal
P450s: for example, polycyclic aromatic hydrocarbons and barbi-
turates such as phenobarbital were among the ﬁrst identiﬁed in-
ducers of CYP1A1 and CYP2B1/2B2 respectively, while gluco-
corticoids such as dexamethasone increase CYP3A4 and ethanol
elevates CYP2E1. Not all forms of P450 are inducible especially the
steroid metabolizing P450s characteristic of the 11, 17, 19, 21 andTable 3
Representative substrates for human liver drug metabolizing CYPS.
CYP1A2- tacrine, theophylline, propranol, imipramine, amitryptyline, phe-
nacetin, caffeine, nifedipine.
CYP2D6- debrisoquine, sparteine, bufuralol, codeine, desipramine, nor-
triptyline, dextromethorphan.
CYP2E1- ethanol, acetaminophen, chlorzoxazone, halothane, enﬂurane, ni-
trosamines, benzene, CCl4.
CYP2C9- tolbutamide, mephenytoin, S-warfarin, diclofenac. ibuprofen,
phenytoin, sulfamethoxazole.
CYP2C19- propranolol, clomipramine, diazepam, omeprazole, progesterone,
cyclophosphamide.
CYP2A6- coumarin, nitrosamines, aﬂatoxin, nicotine, cotinine, testosterone.
CYP3A4/5- nifedipine, cyclosporine, simvastatin, quinidine, midazolam,
lovastatin, dexamethasone.
Table 4
Representative CYP inhibitors and inducers.
Isozyme Inhibitor Inducer
CYP1A2 Cimetidine, ellipticine, benzo(a)pyrene, furafylline, α-naphthoﬂavone. Phenobarbital, omeprazole, rifampin, ritonvair, cyclic aromatic hydrocarbon
CYP2D6 Quinidine, yohimbine, haloperidol, ﬂuoxetine, thioridazine, bupropion. Dexamethasone, carbamazepine, phenytoin, rifampin, ritonavir
CYP2C9 Amiodarone, chloramphenicol, ritonavir, ketoconazole, ﬂuconazole Rifampin, phenobarbital, phenytoin
CYP2C19 Cimetidine, ﬂuoxetine, omeprazole, ritonavir, ketoconazole, sertraline Carbamazepine, phenytoin, rifampin, phenobarbital
CYP2E1 Chlormethiazole, 4-methylpyrazole, disulﬁram, diallyl disulﬁde Ethanol, acetone, isoniazid pyrazole, diabetes
CYP3A4/5 Cimetidine, ketoconazole, ritonavir, azole anti-fungals, grapefruit juice Dexamethazone,barbiturates, carbamazepine, phenytoin, rifampin
Table 5
Polymorphisms of CYP2D6.
Major variant Mutation Consequence
2D6*2Xn Gene duplication Increased activity
2D6*4 Defective splicing Inactive enzyme
2D6*5 Gene deletion No enzyme
2D6*10 P34S, S486T Unstable enzyme
2D6*17 T107L, R296C, S486T Reduced afﬁnity for substrate
Several of the major variants of CYP2D6, the nature of the mutation and the con-
sequences of the polymorphism on content and/or activity of CYP2D6 are shown.
Results modiﬁed from Refs. [58,59].
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CYPs 2B and 2E are inducible (by phenobarbital or ethanol re-
spectively) but CYPs 2A, 2C and 2D are not. Induction of most (but
not all) P450s involves activation of the respective gene and in-
creased de novo protein synthesis. In some cases, speciﬁc cell re-
ceptors which interact with the inducing agent have been identi-
ﬁed e.g. induction of CYP1A1 by polycyclic aromatic hydrocarbons
such as 3-methylcholanthrene involves initial binding of the in-
ducer to the Ah receptor, translocation into the nucleus and
eventual activation of the CYP1A1 gene. Induction of CYP2E1 by
ethanol is complex and involves both transcriptional and post-
transcriptional mechanisms [60]. The CYP2E1 gene is under tran-
scriptional regulation during development and in rats is activated
immediately after birth. Following fasting or induced diabetes,
CYP2E1 mRNA is increased several fold due to post-transcriptional
mRNA stability [61]. The elevation of CYP2E1 by many low mole-
cular weight chemicals including ethanol. acetone, pyrazole is
largely due to protein stabilization and increases in protein half-
life [60,62,63]. Ethanol, at very high levels can also increase
CYP2E1 by a transcriptional mechanism and increased mRNA
synthesis [64]. Thus, multiple mechanisms can exist by which a
cytochrome P450 such as CYP2E1 can be induced.
In many cases, induction of a speciﬁc P450 by a chemical inducer
requires binding of the inducer to a nuclear receptor, followed by
translocation of the receptor-inducer complex into the nucleus and
subsequent interaction and activation of the gene for the P450
[65,66]. Nuclear receptors involved in activating P450 genes include
the constitutive androstane receptor (CAR), the pregnane X receptor
(PXR), the peroxisome proliferator-activated receptors (PPARs), the
aromatic hydrocarbon receptor (AhR) and the farnesoid X receptor
(FXR). The Ah receptor in cooperation with its binding partner
ARNT is involved in induction of CYPs 1A1, 1A2 and 1B1, critical
CYPs involved in carcinogenesis; CYPs 1A1 and 1B1 are mainly
extrahepatic. PXR promotes the induction of CYP3A after forming a
complex with its binding partner retinoid X receptor (RXR); CYP3A4
is responsible for metabolism of many drugs in humans. PPARs are
activated by fatty acids and lipid lowering drugs and induce fatty
acid oxidation enzymes such as peroxisomal acyl CoA oxidase to
promote fat oxidation and removal. Genes induced by CAR include
CYPs 2B6,2C9 and 3A4 as well as several phase 2 conjugation
enzymes. Examples of drugs and substrates for these nuclear
receptors include omeprazole for AhR, phenobarbital for CAR,rifampin for PXR, bile acids for FXR, ﬁbrates for PPAR.
Table 4 lists representative inducers and inhibitors of the major
human liver drug metabolizing CYPs [67].Sex, age and species differences
Levels of the hepatic microsomal mixed function oxidase sys-
tem are very low during fetal development but increase rapidly
soon after birth. There are varying patterns of development de-
pending on the form of P450. In general, drug metabolism activ-
ities stabilize by early adulthood. Studies in rats of varying ages
have suggested that aging is often accompanied by a decline in
metabolism of certain drugs (e.g. [68]). Sex differences, especially
in rats in metabolism of certain drugs have been reported and
certain forms of P450 are present in males e.g. constitutive CYPs
2C11 and 2C13 whereas other forms are present in females e.g.
CYP2C12. Male rats can metabolize certain drugs faster than fe-
males whereas the opposite occurs with other drugs [69].
In mammals, there are wide differences in drug metabolism by
different species. For example, the half life of the barbiturate
hexobarbital has been reported to be 19, 60, 140, and 260 min and
estimated to be 360 min for mice, rabbits, rats, dogs and humans,
respectively [70], results in general agreement with the in vitro
rates of P450-catalyzed metabolism. Imidazole can elevate CYP2E1
in rabbits but not in rats [60]. Strain differences in drug oxidation
are frequently observed in mice. Qualitative and quantitative dif-
ferences in the amount of and form of cytochrome P450s present
account for many of these aging, sex and species differences found.
Human genetic polymorphisms, as discussed above, not only in
drug metabolism P450 enzymes but also in phase 2 conjugation
enzymes such as individuals who are rapid acetylators versus slow
acetylators are especially important in drug development, efﬁcacy
and toxicity. For example, the drugs sparteine and debrisoquine
are metabolized by CYP2D1 [71]. Poor metabolizers of these drugs
are deﬁcient in CYP2D1 and represent a high risk group with re-
spect to adverse drug effects [71].
Diet can have major effects on drug metabolism by modulating
CYP activity [72,73]. Poor nutrition can depress P450-catalyzed
drug oxidations by lowering synthesis and induction of CYPs, by
effects on heme biosynthesis thus altering holoCYP formation and
by modulation of cofactor availability. Various components in the
diet can affect hepatic drug oxidation for example, St. John's wort
can increase hepatic levels of CYP3A4 [74]. CYP inhibitors and
inducers are present in foods [75]. This is especially notable for
components in grapefruit juice such as naringin which is a potent
inhibitor of CYP3A4. Consumption of grapefruit juice is known to
alter the half life and bioavailability of many important clinical
drugs e.g. statins. Isothiocyanates present in cruciferous vegetables
and diallyl disulﬁde present in garlic inhibit CYP2E1 catalytic ac-
tivity. Alcohol increases levels of CYP2E1. Charring of food or
smoke can induce CYP1A2 which can activate many carcinogens.
Levels of CYPs can vary in the fasted versus the fed nutritional
state; for example, levels of CYP2E1 are increased after 24 h of
starvation [60].
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biotics by altering blood ﬂow to the liver due to hepatic vascular
resistance or intrahepatic shunting or extrahepatic shunting of
drugs given orally. Impaired synthesis of plasma proteins such as
albumin may interfere with drug transport of highly protein-
bound drugs in the blood. A decrease in the number of viable
hepatocytes or lower activity of residual hepatocytes will lower
P450-catalyzed drug oxidation. Cofactor availability, not always
considered, may also be compromised by glycogen depletion or
pentose cycle impairment and under certain conditions, NADPH
may be a limiting factor in overall drug oxidation by P450 [76].
There is a zonal distribution of P450 in the liver acinus as the
centrilobular region of the liver generally contains a higher
amount of P450 than the periportal zone. For example, CYP2E1 is
present, especially after induction by ethanol in the centrilobular
zone of the liver [77]. Interestingly, this may, along with other
factors (lower oxygen tension, lower levels of GSH), contribute to
the initiation and increased toxicity of agents oxidized by CYP2E1
to reactive products including CCl4, acetaminophen, benzene and
ethanol itself in the centrilobular zone. A review of the effects of
diseases and environmental factors on human CYPs can be found
in [78].Reactive oxygen formation (ROS)
As mentioned above, small amounts of ROS such as superoxide
radical anion and H2O2 are produced during the P450 catalytic
cycle and cytochrome P450 enzymes are a signiﬁcant source of
ROS in biological systems, especially tissues like the liver where
P450 is present in high amounts. Several factors determine the
generation of ROS by P450s including the speciﬁc form of P450,Fig. 10. Microsomal production of superoxide anion radical. Microsomes were isolated
oxide was assayed by determining the superoxide dismutase-sensitive production of the
tetramethyl-4-oxo-piperidine. Either NADPH (spectra b and c) or NADH (spectra d and e)
a ﬂat quartz cuvette using a Bruker E-300 spectrometer. Spectrum a is that of 0.04 mM
¼16.0 G and g¼2.005. Results are from Refs. [80,81].entry of the second electron into the P450 cycle, the presence of
substrate and nature of the substrate [40–43]. The toxicity of many
reagents is due, in part, to increased production of ROS when they
are metabolized by cytochrome P450s e.g. CCL4, halogenated hy-
drocarbons, benzene, acetaminophen, anesthetics, nitrosamines
etc. CYP2E1 appears to be signiﬁcant generator of ROS and this
may play a role in alcohol-induced liver toxicity [79]. Using
CYP2E1 as the representative P450 enzyme, some examples of ROS
production by microsomes are brieﬂy presented below. Fig. 10
shows the generation of superoxide from liver microsomes iso-
lated from chronic ethanol-fed rats (in which CYP2E1 is elevated)
and their pair-fed dextrose controls [80,81]. Superoxide was as-
sayed by electron resonance spectroscopy from the interaction of
superoxide with a chemical probe which produces a stable ni-
troxyl radical with deﬁned splitting constants. Superoxide was
produced when either NADPH or NADH was the microsomal re-
ductant, however, rates of superoxide production were about 3–4
times greater with NADPH (Fig. 10 spectra b and c) than with
NADH (Fig. 10 spectra d and e) with either microsomes from the
ethanol-fed or the control rats, in agreement with NADPH being
the preferred reductant for the liver microsomal mixed function
oxidase system. The rates of superoxide production by microsomes
from the ethanol-fed rats were greater with NADH or especially
NADPH as the reductants as compared to the microsomes from the
control rats. All ESR signals were decreased more than 80% by
superoxide dismutase validating the role of superoxide in produ-
cing the ESR signal. The increase in the ESR signal by the micro-
somes from the ethanol-fed rats was blunted by an antibody
against CYP2E1, suggesting that induction of CYP2E1 by ethanol
played a role in the increase in microsomal superoxide generation.
Fig. 11 shows that chronic ethanol feeding for 4 weeks in-
creased liver lipid peroxidation as compared to the pair-fedfrom chronic ethanol-fed rats and dextrose pair-fed controls. Generation of super-
nitroxyl radical formed from the interaction of superoxide with 1-hydroxy-2,2,6,6-
were used as cofactors. ESR measurements were carried out at room temperature in
of a standard nitroxyl radical. Splitting constants for the resulting triplet were AN
Fig. 11. Chlormethiazole (CMZ) lowers alcohol-induced oxidant stress. SV129 fe-
male mice were fed the Lieber-DeCarli ethanol or dextrose liquid diets for 4 weeks.
At 2 weeks, some of the ethanol-fed mice were also treated with the CYP2E1 in-
hibitor, CMZ, at a dose of 50 mg/kg body wt, IP, every other day and fed ethanol for
the remaining 2 weeks. Lipid peroxidation in liver homogenates was determined by
a thiobarbituric acid (TBARs) assay. Immunohistochemical staining for 3-nitrotyr-
osine (3-NT) protein adducts or 4-hydroxynonenal (4-HNE) protein adducts was
carried out using anti-3-NT or 4-HNE antibodies, followed by a rabbit ABC staining
system (Santa Cruz). Results are from Ref. [82].
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CYP2E1 and Alcohol-induced Oxidant Stress
Fig. 12. Alcohol-induced oxidant stress is lower in CYP2E1 knockout (KO) mice.
CYP2E1 KO mice and CYP2E1 knockin (KI) mice in which the human 2E1 transgene
was introduced into the corresponding mouse null mice to produce a humanized
CYP2E1 in the mouse background in the absence of the mouse CYP2E1, were kindly
provided by Dr. Frank Gonzalez, NCI, NIH [83,84]. SV129 female wild type (WT) and
the KO and the KI mice were fed the ethanol or dextrose diets for 4 weeks. Liver
homogenates (1:10) were prepared in 150 mM KCl and assayed for TBARs and for
total GSH levels. Results are from Ref. [85].
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showed that the ethanol feeding increased levels of 3-nitrotyr-
osine protein adducts and 4-hydroxynonenal protein adducts. In-
creases in these adducts occurred mostly in the pericentral zone of
the liver acinus, the area where alcohol injury in the liver is in-
itiated. Chlormethiazole, a potent inhibitor of CYP2E1, blocked
these increases in TBARs and 3-NT and 4-HNE adducts (Fig. 11)
[82]. Another approach to evaluate the role of a CYP in ROS gen-
eration is to use knockout (KO) mice [83,84]. Fig. 12 shows that
chronic ethanol treatment increased levels of TBARs in wild type
(WT) mice about 2-fold. No such increases were observed in
CYP2E1 KO mice, whereas even greater increases in TBARs were
seen in CYP2E1 KI mice in which high levels of CYP2E1 were re-
stored in the KO mice [85]. Similar results were found with respect
to hepatic GSH levels; GSH was lowered by ethanol feeding in WT
and KI mice but not in KO mice (Fig. 12). Thus, CYPs such as
CYP2E1 can produce ROS and increases in ROS production can
occur due to induction of CYP2E1. Use of speciﬁc inhibitors or
appropriate knockout mice are tools to allow evaluation of the role
of a speciﬁc CYP in ROS production or the elevation in ROS pro-
duction by a speciﬁc treatment.Personalized medicine
Personalized medicine refers to the customization of healthcare
using molecular analysis and tailoring an individual's medicalapproach and treatment according to his/her genetic information
[86,87]. Selection of an individual's appropriate and optimal
therapy is based, in part, on the patient's genetic content. This has
been successfully applied to pharmacogenomics of the applied
therapy which is largely based on evaluation of the presence or
absence of speciﬁc CYPs and of CYP polymorphisms which are
present. Personalized medicine can be used to predict a person's
risk for a particular disease based on the presence or absence of a
speciﬁc gene. With respect to drug therapy, the drug chosen and
the dosage used may be due, in part, to the content of CYPs and the
presence of certain CYP polymorphisms. Knowledge of the CYPs
present and their polymorphic forms can be useful for inclusion or
exclusion of certain individual’s in clinical trials of new drugs and
may increase safety and lower adverse outcomes caused by the
drug being tested [88,89]. This information may also lower trial
and error approaches to ﬁnd the most appropriate therapy effec-
tive for the patient [88,89]. According to the Personalized Medical
Coalition, 137 FDA-approved drugs have pharmacogenomic in-
formation in their labeling and 155 pharmacogenomic biomarkers
are included in FDA-approved drug labeling. Many of these labels
include information on the role of CYPs and effect of polymorphic
CYPs on metabolism of the drug [88,89].
The major factor for interindividual differences in drug re-
sponse is the variable pharmacokinetics, which are due mainly to
differences in the content and activity of the CYPs which meta-
bolize the drug. About 50% of human drug metabolism is mainly
carried out by the highly polymorphic CYP enzymes, CYP2C9, 2C19
and 2D6 (Table 2). Resulting phenotypes in response to a drug may
depend on the speciﬁc polymorphism e.g single nucleotide poly-
morphism, insertion, deletion, copy number variation (Table 5 for
CYP2D6) which can give rise to ultrarapid metabolizers (UMs),
extensive metabolizers (EMs), intermediate metabolizers (IMs)
and poor metabolizers (PMs) [53,56,59]. Problems associated with
UMs include lack of a response to the drug when administered at
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tion of toxic metabolites. PMs have a risk of no therapeutic re-
sponse and increased risk of adverse drug reactions. For example,
for the CYP2D6*1/*2XN which displays gene duplication, there is
poor or no response to antiemetics or antidepressants; the latter
was associated with increased suicide risk [88]. For the CYP2D6*4
or *5 polymorphisms, which are PMs, there is reduced response to
antianalgesics [88]. Besides detoxifying and eliminating drugs, the
liver microsomal CYPs are often required to activate certain pro-
drugs to the active form. Many opiod analgesics are activated by
CYP2D6 and in view of the many polymorphisms of CYP2D6, many
individuals are relatively insensitive to the analgesic actions of e.g.
codeine and there is much interindividual variation in the efﬁcacy
of pain relief when “normal” doses of codeine or ethylmorphine
are administered. A good example on how CYP2D6 polymorph-
isms affect the necessary maintenance dosage of a drug is the
study by Zanger et al. [90]. The doses of nortriptyline required to
achieve therapeutics were about 50 mg in PMs, about 50–100 mg
in IMs, 100–150 mg in EMs and 500 mg in UMs. Such differences in
required maintenance dosages were in accordance with rates of
bufuralol hydroxylation, a marker substrate for CYP2D6 activity.
Warfarin is a widely used oral anticoagulant but has a narrow
therapeutic window and there is difﬁculty in management of effective
maintenance doses. Warfarin is metabolized by CYP2C9 and ethnic
differences in warfarin maintenance doses requirements are related to
CYP2C9 polymorphisms [91]. African-Americans require a higher
warfarin dose (about 6 mg/day) while Asians require a lower warfarin
maintenance dose (about 3.5 mg/day) compared to Caucasians (about
5 mg/day) [92]. There are many polymorphic forms of CYP2C9; Cau-
casians possess mainly the CYP2C9*2 and *3 forms and Asians contain
mainly the CYP2C9*3 form. These polymorphisms reduce CYP2C9
metabolism of warfarin leading to requirement of lower maintenance
doses than in African-Americans in which these two polymorphic
forms of CYP2C9 are lower and the authors concluded that additional
studies on polymorphic forms of CYP2C9 are needed [92]. Allele fre-
quencies also can differ between Caucasians and Orientals e.g. the
CYP2D6*4 allele shows a 12–21% frequency is Caucasians but only a 1%
frequency is Orientals while the CYP2D6*10 allele has a frequency of
1–2% in Caucasians but a 50% frequency in Orientals [58], likely con-
tributing to differences in drug responses between these two ethnic
groups. Table 3 of Ref. [59] shows the ethnic distribution of the most
common variant alleles of CYP2D6 among Caucasians, Asians, Black
Africans and Ethiopians/ Saudi Arabians e.g. the latter have the highest
frequency of the CYP2D6*2Xn allele which displays gene duplication
and increased enzyme activity; such considerations play critical roles
in personalized medicine.
Besides the importance of phase I CYPs in personalized medi-
cine, there are also polymorphisms in phase 2 conjugation en-
zymes which play signiﬁcant roles in individual differences to
drugs e.g. the N-acetyl transferases which can cause the “slow
acetylator” phenotype with respect to certain drugs such as iso-
niazid or hydralazine or sulfamethoxazole [93].
In view of the importance of the liver microsomal CYPs in per-
sonalized medicine, identifying which CYPs and which polymorphic
forms are present is of major value in choosing the most appro-
priate drug and drug dosage. The concept of CYP on a chip has been
developed as a major tool for this. For example, the AmpliChip
CYP450 (Roche Molecular Diagnostic) test evaluates the CYP2D6
genotype and makes phenotype predictions [94]. This chip allows
simultaneous analysis of 33 CYP2D6 alleles [94]. Rabsamen et al.
[95] veriﬁed the genotyping accuracy of the chip for the 5 major
CYP2D6 alleles and conﬁrmed these results with real time PCR. An
updated version of the AmpliChip contains 3 CYP19 alleles in ad-
dition to the 33 CYP2D6 alleles with the goal “to help clinicians
determine therapeutic strategy and treatment doses for therapeutic
metabolism by the CYP2D6 and CYP2C19” [96].Conclusions
Because of many of the above described factors modulating levels
of CYPs as well as polymorphisms of many CYPs, there is large
variability in content of the xenobiotic metabolizing CYPs in families
1, 2 and 3 in human livers, which likely accounts for the large
variability in drug oxidation by humans. Guengerich evaluated the
levels of CYPs 1A2, 2E1 and 3A4 in 18 human liver samples [37].
There were 5–10 folds differences in levels of each of the 3 CYPs
among the 18 samples [37]. Because of this variability in levels of a
speciﬁc P450, the presence of multiple CYPs with overlapping sub-
strate speciﬁcity and the ability of a CYP to metabolize many
structurally distinct substrates, there is extensive overlapping sub-
strate speciﬁcities which likely contributes to drug–drug interactions
and adverse drug reactions [97]. Attempts to minimize such adverse
effects will require further studies on structure–function relation-
ships of CYP enzymes, further information on links between CYP
polymorphisms and disease/toxicity, identiﬁcation of what are the
substrates for orphan CYPs [98], and developing bioinformatic
models to predict whether certain drugs and chemicals may be toxic
or carcinogenic or act to induce a CYP. Development of designer
CYPs which may be useful in removal of toxins, pollutants, oil etc.
and engineering CYPs to extend their catalytic capabilities as dis-
cussed in Refs. [99,100] are likely to further extend the activities of
this versatile family of enzymes.Acknowledgments
Original data were supported by grants from the National In-
stitute on Alcohol Abuse and Alcoholism, USPHS AA-017425, AA-
018790 and AA-021362.References
[1] D.W. Nebert, D.R. Nelson, M.J. Coon, R.W. Estabrook, R. Feyereisen, Y. Fujii-
Kuriyama, F.J. Gonzalez, F.P. Guengerich, I.C. Gunsalus, E.F. Johnson, J.C. Loper,
R. Sato, M.R. Waterman, D.J. Waxman, The P450 superfamily: update on new
sequences, gene mapping, and recommended nomenclature, DNA and Cell
Biology 10 (1991) 1–4.
[2] R.A. McKinnon, M.J. Sorich, M.B. Ward, Cytochrome P450 Part 1: multiplicity
and function, Journal of Research in Pharmacy Practice 38 (2008) 55–57.
[3] B. Kalyanaraman, Teaching the basics of redox biology to medical and
graduate students: oxidants, antioxidants and disease mechanisms, Redox
Biology 1 (2013) 244–257. http://dx.doi.org/10.1016/j.redox.2013.01.014
24024158.
[4] M. Klingenberg, Pigments of rat liver microsomes, Archives of Biochemistry
and Biophysics 75 (2) (1958) 376–386. http://dx.doi.org/10.1016/0003-9861
(58)90436-3 13534720.
[5] D. Garﬁnkel, Studies on pig liver microsomes. I. Enzymic and pigment
composition of different microsomal fractions, Archives of Biochemistry and
Biophysics 77 (1958) 493–509.
[6] T. Omura, R. Sato, The carbon monoxide-binding pigment of liver micro-
somes. I: Evidence for its hemoprotein nature, Journal of Biological Chem-
istry 239 (1964) 2370–2378.
[7] F.P. Guengerich, M.V. Martin, C.D. Sohl, Q. Cheng, Measurement of cyto-
chrome P450 and NADPH-cytochrome P450 reductase, Nature Protocols 4
(2009) 1245–1251. http://dx.doi.org/10.1038/nprot.2009.121 19661994.
[8] D.Y. Cooper, S. Levin, S. Narasimhulu, O. Rosenthal, R.W. Estabrook, Photo-
chemical action spectrum of the terminal oxidase of mixed function oxidase
systems, Science 147 (3656) (1965) 400–402. http://dx.doi.org/10.1126/sci-
ence.147.3656.400 14221486.
[9] R. Sato, T. Omura, Cytochrome P450, Kodansha Ltd., Tokyo, 1978.
[10] A.H. Conney, Pharmacological implications of microsomal enzyme induction,
Pharmacological Reviews 19 (3) (1967) 317–366.
[11] M. Romano, T. Facchinetti, M. Salmona, Is there a role for nuclei in the me-
tabolism of xenobiotica? A review, Drug Metabolism Reviews 14 (4) (1983)
803–829. http://dx.doi.org/10.3109/03602538308991409 6413186.
[12] J. Loeper, V. Descatoire, M. Maurice, P. Beaune, G. Feldmann, D. Larrey, Pre-
sence of functional cytochrome P-450 on isolated rat hepatocyte plasma
membrane, Hepatology 11 (1990) 850–858.
A.I. Cederbaum / Redox Biology 4 (2015) 60–7372[13] J.B. Schenkman, I. Jansson, Spectral analyses of cytochromes P450, Methods
in Molecular Biology 320 (2006) 11–18. http://dx.doi.org/10.1385/1-59259-
998-2:11 16719370.
[14] E.M. Isin, F.P. Guengerich, Substrate binding to cytochromes P450, Analytical
and Bioanalytical Chemistry 392 (6) (2008) 1019–1030. http://dx.doi.org/
10.1007/s00216-008-2244-0 18622598.
[15] D.E. Feierman, A.I. Cederbaum, Increased sensitivity of the microsomal oxi-
dation of ethanol to inhibition by pyrazole and 4-methylpyrazole after
chronic ethanol treatment, Biochemical Pharmacology 36 (19) (1987)
3277–3283. http://dx.doi.org/10.1016/0006-2952(87)90645-9 3663241.
[16] T. Omura, E. Sanders, R.W. Estabrook, D.Y. Cooper, O. Rosenthal, Isolation
from adrenal cortex of a nonheme iron protein and a ﬂavoprotein functional
as a reduced triphosphopyridine nucleotide-cytochrome P-450 reductase,
Archives of Biochemistry and Biophysics 117 (3) (1966) 660–672. http://dx.
doi.org/10.1016/0003-9861(66)90108-1.
[17] D.W. Cushman, R.L. Tsai, I.C. Gunsalus, The ferroprotein component of a
methylene hydroxylase, Biochemical and Biophysical Research Communica-
tions 26 (5) (1967) 577–583. http://dx.doi.org/10.1016/0006-291X(67)90104-
0 4383050.
[18] A.Y.H. Lu, M.J. Coon, Role of hemoprotein P450 in fatty acid omega hydro-
xylation in a soluble enzyme system from liver microsomes, Journal of Bio-
logical Chemistry 242 (1973) 2297–2308.
[19] D.S. Riddick, X. Ding, C.R. Wolf, T.D. Porter, A.V. Pandey, Q.Y. Zhang, J. Gu,
R.D. Finn, S. Ronseaux, L.A. McLaughlin, C.J. Henderson, L. Zou, C.E. Flück,
NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology
and toxicology, Drug Metabolism and Disposition 41 (1) (2013) 12–23. http:
//dx.doi.org/10.1124/dmd.112.048991 23086197.
[20] M.J. Coon, Cytochrome P450: nature's most versatile biological catalyst,
Annual Review of Pharmacology and Toxicology 45 (2005) 1–25. http://dx.
doi.org/10.1146/annurev.pharmtox.45.120403.100030 15832443.
[21] L. Koymans, G.M. Donne-Op Den Kelder, J.M. Koppele Te, N.P. Vermeulen,
Cytochromes P450: their active-site structure and mechanism of oxidation,
Drug Metabolism Reviews 25 (3) (1993) 325–387. http://dx.doi.org/10.3109/
03602539308993979 8404461.
[22] L. Spatz, P. Strittmatter, A form of reduced nicotinamide adenine dinucleo-
tide-cytochrome b 5 reductase containing both the catalytic site and an
additional hydrophobic membrane-binding segment, Journal of Biological
Chemistry 248 (3) (1973) 793–799 4346350.
[23] B. Kemper, E. Szczesna-Skorupa, Cytochrome P-450 membrane signals, Drug
Metabolism Reviews 20 (2–4) (1989) 811–820. http://dx.doi.org/10.3109/
03602538909103580.
[24] S.D. Black, Membrane topology of the mammalian P450 cytochromes, FASEB
Journal 6 (1992) 680–685.
[25] E.P.A. Neve, M. Hidestrand, M. Ingelman-Sundberg, Identiﬁcation of se-
quences responsible for intracellular targeting and membrane binding of rat
CYP2E1 in yeast, Biochemistry 42 (49) (2003) 14566–14575. http://dx.doi.
org/10.1021/bi035193s 14661969.
[26] P. Baranczewski, A. Stańczak, K. Sundberg, R. Svensson, A. Wallin, J. Jansson,
P. Garberg, H. Postlind, Introduction to in vitro estimation of metabolic sta-
bility and drug interactions of new chemical entities in drug discovery and
development, Pharmacological Reports 58 (4) (2006) 453–472.
[27] P.R. Ortiz de Montellano, Cytochrome P450. Structure, Mechanism and Bio-
chemistry, Plenum Press, NY., 1986.
[28] L.P. James, P.R. Mayeux, J.A. Hinson, Acetaminophen-induced hepatotoxicity,
Drug Metabolism and Disposition 31 (12) (2003) 1499–1506. http://dx.doi.
org/10.1124/dmd.31.12.1499 14625346.
[29] C. Saito, C. Zwingmann, H. Jaeschke, Novel mechanisms of protection against
acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine,
Hepatology 51 (1) (2010) 246–254. http://dx.doi.org/10.1002/hep.23267
19821517.
[30] D. Mansuy, The great diversity of reactions catalyzed by cytochromes P450,
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology
and Endocrinology 121 (1998) 5–14. http://dx.doi.org/10.1016/S0742-8413
(98)10026-9 9972447.
[31] U.M. Zanger, M. Schwab, Cytochrome P450 enzymes in drug metabolism:
regulation of gene expression, enzyme activities. and impact of genetic
variation, Pharmacology and Therapeutics 138 (1) (2013) 103–141. http://dx.
doi.org/10.1016/j.pharmthera.2012.12.007.
[32] T.D. Porter, M.J. Coon, Cytochrome P-450. Multiplicity of isoforms, substrates,
and catalytic and regulatory mechanisms, Journal of Biological Chemistry
266 (21) (1991) 13469–13472.
[33] D.C. Lamb, M.R. Waterman, S.L. Kelly, F.P. Guengerich, Cytochromes P450 and
drug discovery, Current Opinion in Biotechnology 18 (6) (2007) 504–512.
http://dx.doi.org/10.1016/j.copbio.2007.09.010 18006294.
[34] F.P. Guengerich, Cytochrome p450 and chemical toxicology, Chemical Re-
search in Toxicology 21 (1) (2008) 70–83. http://dx.doi.org/10.1021/
tx700079z 18052394.
[35] F.P. Guengerich, Oxidation of toxic and carcinogenic chemicals by human
cytochrome P-450 enzymes, Chemical Research in Toxicology 4 (1991)
391–407.
[36] I.A. Pikuleva, M.R. Waterman, Cytochromes P450: roles in diseases, Journal of
Biological Chemistry 288 (24) (2013) 17091–17098. http://dx.doi.org/
10.1074/jbc.R112.431916 23632021.
[37] F.P. Guengerich, Cytochrome P450s and other enzymes in drug metabolism
and toxicity, AAPS Journal 8 (2006) E101–E111. http://dx.doi.org/10.1208/
aapsj080112 16584116.[38] F.P. Guengerich, Common and uncommon cytochrome P450 reactions re-
lated to metabolism and chemical toxicity, Chemical Research in Toxicology
14 (6) (2001) 611–650. http://dx.doi.org/10.1021/tx0002583 11409933.
[39] C.S. Yang, J.S. Yoo, H. Ishizaki, J.Y. Hong, Cytochrome P450IIE1: roles in ni-
trosamine metabolism and mechanisms of regulation, Drug Metabolism
Reviews 22 (2–3) (1990) 147–159. http://dx.doi.org/10.3109/
03602539009041082 2272285.
[40] H. Kuthan, V. Ullrich, Oxidase and oxygenase function of the microsomal
cytochrome P450 monooxygenase system, European Journal of Biochemistry
126 (3) (1982) 583–588. http://dx.doi.org/10.1111/j.1432-1033.1982.tb06820.
x 7140747.
[41] J. Blanck, O. Ristau, A.A. Zhukov, A.I. Archakov, H. Rein, K. Ruckpaul, Cyto-
chrome P-450 spin state and leakiness of the monooxygenase pathway,
Xenobiotica 21 (1) (1991) 121–135. http://dx.doi.org/10.3109/
00498259109039456 1848383.
[42] R.E. White, M.J. Coon, Oxygen activation by cytochrome P-450, Annual Re-
view of Biochemistry 49 (1980) 315–356. http://dx.doi.org/10.1146/annurev.
bi.49.070180.001531 6996566.
[43] D. Pompon, Rabbit liver cytochrome P-450 LM2: roles of substrates, in-
hibitors, and cytochrome b5 in modulating the partition between productive
and abortive mechanisms, Biochemistry 26 (20) (1987) 6429–6435. http:
//dx.doi.org/10.1021/bi00394a020 3501314.
[44] L.A. McLaughlin, S. Ronseaux, R.D. Finn, C.J. Henderson, C. Roland Wolf,
Deletion of microsomal cytochrome b5 profoundly affects hepatic and ex-
trahepatic drug metabolism, Molecular Pharmacology 78 (2) (2010)
269–278. http://dx.doi.org/10.1124/mol.110.064246 20430864.
[45] C.J. Henderson, L.A. McLaughlin, C.R. Wolf, Evidence that cytochrome b5 and
cytochrome b5 reductase can act as sole electron donors to the hepatic cy-
tochrome P450 system, Molecular Pharmacology 83 (6) (2013) 1209–1217.
http://dx.doi.org/10.1124/mol.112.084616 23530090.
[46] G.T. Miwa, S.B. West, A.Y. Lu, Studies on the rate-limiting enzyme component
in the microsomal monooxygenase system. Incorporation of puriﬁed
NADPH-cytochrome c reductase and cytochrome P-450 into rat liver mi-
crosomes, Journal of Biological Chemistry 253 (6) (1978) 1921–1929.
[47] G.T. Miwa, N. Harada, A.Y. Lu, Kinetic isotope effects on cytochrome P-450-
catalyzed oxidation reactions: full expression of the intrinsic isotope effect
during the O-deethylation of 7-ethoxycoumarin by liver microsomes from
3-methylcholanthrene-induced hamsters, Archives of Biochemistry and
Biophysics 239 (1) (1985) 155–162. http://dx.doi.org/10.1016/0003-9861(85)
90822-7 4004255.
[48] L.D. Gorsky, D.R. Koop, M.J. Coon, On the stoichiometry of the oxidase and
monooxygenase reactions catalyzed by liver microsomal cytochrome P-450.
Products of oxygen reduction, Journal of Biological Chemistry 259 (11)
(1984) 6812–6817.
[49] G. Ekström, M. Ingelman-Sundberg, Rat liver microsomal NADPH-supported
oxidase activity and lipid peroxidation dependent on ethanol-inducible cy-
tochrome P-450 (P-450IIE1), Biochemical Pharmacology 38 (8) (1989)
1313–1319. http://dx.doi.org/10.1016/0006-2952(89)90338-9 2495801.
[50] F.P. Guengerich, T.L. MacDonald, Chemical mechanisms of catalysis by cyto-
chromes P-450: a uniﬁed view, Accounts of Chemical Research 17 (1) (1984)
9–16. http://dx.doi.org/10.1021/ar00097a002.
[51] F.P. Guengerich, Chemical mechanisms of cytochrome P450 catalysis, Asia
Paciﬁc Journal of Pharmacology 5 (1990) 253–268.
[52] M.J. Coon, X.X. Ding, S.J. Pernecky, A.D.N. Vaz, Cytochrome P450: progress
and predictions, FASEB Journal 6 (1992) 669–673.
[53] M. Ingelman-Sundberg, Pharmacogenetics of cytochrome P450 and its ap-
plications in drug therapy: the past, present and future, Trends in Pharma-
cological Sciences 25 (4) (2004) 193–200. http://dx.doi.org/10.1016/j.
tips.2004.02.007 15063083.
[54] F.P. Guengerich, S. Rendic, Update information on drug metabolism systems
– 2009, Part 1, Current Drug Metabolism 11 (2010) 1–3.
[55] S. Rendic, F.P. Guengerich, Contributions of human enzymes in carcinogen
metabolism, Chemical Research in Toxicology 25 (7) (2012) 1316–1383. http:
//dx.doi.org/10.1021/tx300132k 22531028.
[56] S.C. Sim, M. Kacevska, M. Ingelman-Sundberg, Pharmacogenomics of drug-
metabolizing enzymes: a recent update on clinical implications and en-
dogenous effects, Pharmacogenomics Journal 13 (1) (2013) 1–11. http://dx.
doi.org/10.1038/tpj.2012.45 23089672.
[57] U.M. Zanger, K. Klein, M. Thomas, J.K. Rieger, R. Tremmel, B.A. Kandel,
M. Klein, T. Magdy, Genetics, epigenetics, and regulation of drug-metabo-
lizing cytochrome P450 enzymes, Clinical Pharmacology and Therapeutics
95 (3) (2014) 358–361. http://dx.doi.org/10.1038/clpt.2013.220 24196843.
[58] M. Ingelman-Sundberg, Genetic susceptibility to adverse effects of drugs and
environmental toxicants. The role of the CYP family of enzymes, Mutation
Research 482 (1–2) (2001) 11–19. http://dx.doi.org/10.1016/S0027-5107(01)
00205-6 11535244.
[59] M. Ingelman-Sundberg, Genetic polymorphisms of cytochrome P450 2D6
(CYP2D6): clinical consequences, evolutionary aspects and functional di-
versity, Pharmacogenomics Journal 5 (1) (2005) 6–13. http://dx.doi.org/
10.1038/sj.tpj.6500285 15492763.
[60] D.R. Koop, D.J. Tierney, Multiple mechanisms in the regulation of ethanol-
inducible cytochrome P450IIE1, BioEssays 12 (1990) 429–435. http://dx.doi.
org/10.1002/bies.950120906 2256907.
[61] B.J. Song, T. Matsunaga, J.P. Hardwick, S.S. Park, R.L. Veech, Stabilization of cyto-
chrome P450j messenger ribonucleic acid in the diabetic rat, Molecular En-
docrinology 1 (1987) 542–547. http://dx.doi.org/10.1210/mend-1-8-542 3153476.
A.I. Cederbaum / Redox Biology 4 (2015) 60–73 73[62] B.J. Song, H.V. Gelboin, S.S. Park, C.S. Yang, F.J. Gonzalez, Complementary DNA
and protein sequences of ethanol-inducible rat and human cytochrome
P-450s. Transcriptional and post-transcriptional regulation of the rat en-
zyme, Journal of Biological Chemistry 261 (35) (1986) 16689–16697.
[63] B.J. Song, R.L. Veech, S.S. Park, H.V. Gelboin, F.J. Gonzalez, Induction of rat
hepatic N-nitrosodimethylamine demethylase by acetone is due to protein
stabilization, Journal of Biological Chemistry 264 (6) (1989) 3568–3572.
[64] M.J. Ronis, J. Huang, J. Crouch, C. Mercado, D. Irby, C.R. Valentine,
C.K. Lumpkin, M. Ingelman-Sundberg, T.M. Badger, Cytochrome P450
CYP2E1 induction during chronic alcohol exposure occurs by a two-step
mechanism associated with blood alcohol concentrations in rats, Journal of
Pharmacology and Experimental Therapeutics 264 (2) (1993) 944–950.
[65] P. Honkakoski, M. Negishi, Regulation of cytochrome P450 (CYP) genes by
nuclear receptors, Biochemical Journal 347 (2) (2000) 321–337. http://dx.doi.
org/10.1042/0264-6021:3470321 10749660.
[66] D.J. Waxman, P450 gene induction by structurally diverse xenochemicals:
central role of nuclear receptors CAR, PXR, and PPAR, Archives of Biochem-
istry and Biophysics 369 (1) (1999) 11–23. http://dx.doi.org/10.1006/
abbi.1999.1351 10462436.
[67] O. Pelkonen, M. Turpeinen, J. Hakkola, P. Honkakoski, J. Hukkanen, Inhibition
and induction of human cytochrome P450 enzymes: current status, Archives
of Toxicology 82 (10) (2008) 667–715. http://dx.doi.org/10.1007/s00204-
008-0332-8 18618097.
[68] J. Roberts, N. Tumer, Age and diet effects on drug action, Pharmacology and
Therapeutics 37 (1) (1988) 111–127. http://dx.doi.org/10.1016/0163-7258(88)
90022-8 3289052.
[69] D.L. Schmucker, K.W. Woodhouse, R.K. Wang, H. Wynne, O.F. James,
M. McManus, P. Kremers, Effects of age and gender on in vitro properties of
human liver microsomal monooxygenases, Clinical Pharmacology and
Therapeutics 48 (4) (1990) 365–374. http://dx.doi.org/10.1038/clpt.1990.164
2121408.
[70] G.P. Quinn, J. Axelrod, B.B. Brodie, Species, strain and sex differences in
metabolism of hexobarbitone, amidopyrine, antipyrine and aniline, Bio-
chemical Pharmacology 1 (1958) 152–159. http://dx.doi.org/10.1016/0006-
2952(58)90024-8.
[71] U.A. Meyer, R.C. Skoda, U.M. Zanger, The genetic polymorphism of debriso-
quine/sparteine metabolism-molecular mechanisms, Pharmacology and
Therapeutics 46 (2) (1990) 297–308. http://dx.doi.org/10.1016/0163-7258
(90)90096-K 2181495.
[72] C. Ioannides, Effect of diet and nutrition on the expression of cytochromes
P450, Xenobiotica 29 (2) (1999) 109–154. http://dx.doi.org/10.1080/
004982599238704 10199591.
[73] F.P. Guengerich, Inﬂuence of nutrients and other dietary materials on cyto-
chrome P-450 enzymes, American Journal of Clinical Nutrition 61 (Suppl. 3)
(1995) 651S–658S.
[74] B.J. Komoroski, S. Zhang, H. Cai, M. Hutzler, R. Frye, T.S. Tracy, S.C. Strom,
T. Lehmann, C.Y.W. Ang, Y.Y. Cui, R. Venkataramanan, Induction and inhibi-
tion of cytochromes P450 by the St. John's wort constituent hyperforin in
human hepatocyte cultures, Drug Metabolism and Disposition 32 (5) (2004)
512–518. http://dx.doi.org/10.1124/dmd.32.5.512.
[75] E.H. Jang, Y.C. Park, W.G. Chung, Effects of dietary supplements on induction
and inhibition of cytochrome P450s protein expression in rats, Food and
Chemical Toxicology 42 (11) (2004) 1749–1756. http://dx.doi.org/10.1016/j.
fct.2004.07.001 15350672.
[76] R.G. Thurman, F.C. Kauffman, Factors regulating drug metabolism in intact
hepatocytes, Pharmacological Reviews 31 (4) (1979) 229–261.
[77] M. Ingelman-Sundberg, I. Johansson, K.E. Penttilä, H. Glaumann, K.O. Lindros,
Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat
liver, Biochemical and Biophysical Research Communications 157 (1) (1988)
55–60. http://dx.doi.org/10.1016/S0006-291X(88)80010-X 2904264.
[78] S. Rendic, F.P. Guengerich, Update information on drug metabolism systems-
2009, Part II: Summary of information on the effects of diseases and en-
vironmental factors on human cytochrome P450 (CYP) enzymes and trans-
porters, Current Drug Metabolism 11 (2010) 4–84.
[79] A.I. Cederbaum, Y. Lu, D. Wu, Role of oxidative stress in alcohol-induced liver
injury, Archives of Toxicology 83 (6) (2009) 519–548. http://dx.doi.org/
10.1007/s00204-009-0432-0 19448996.
[80] J. Rashba-Step, N.J. Turro, A.I. Cederbaum, ESR studies on the production of
reactive oxygen intermediates by rat liver microsomes in the presence of
NADPH or NADH, Archives of Biochemistry and Biophysics 300 (1) (1993)
391–400. http://dx.doi.org/10.1006/abbi.1993.1053 8380968.
[81] J. Rashba-Step, N.J. Turro, A.I. Cederbaum, Increased NADPH- and NADH-
dependent production of superoxide and hydroxyl radical by microsomes
after chronic ethanol treatment, Archives of Biochemistry and Biophysics
300 (1) (1993) 401–408. http://dx.doi.org/10.1006/abbi.1993.1054 8380969.
[82] Y. Lu, J. Zhuge, X. Wang, J. Bai, A.I. Cederbaum, Cytochrome P450 2E1contributes to ethanol-induced fatty liver in mice, Hepatology 47 (5) (2008)
1483–1494. http://dx.doi.org/10.1002/hep.22222 18393316.
[83] S.S. Lee, J.T. Buters, T. Pineau, P. Fernandez-Salguero, F.J. Gonzalez, Role of
CYP2E1 in the hepatotoxicity of acetaminophen, Journal of Biological
Chemistry 271 (20) (1996) 12063–12067. http://dx.doi.org/10.1074/
jbc.271.20.12063 8662637.
[84] C. Cheung, A.M. Yu, J.M. Ward, K.W. Krausz, T.E. Akiyama, L. Feigenbaum,
F.J. Gonzalez, The cyp2e1-humanized transgenic mouse: role of cyp2e1 in
acetaminophen hepatotoxicity, Drug Metabolism and Disposition 33 (3)
(2005) 449–457. http://dx.doi.org/10.1124/dmd.104.002402 15576447.
[85] Y. Lu, D. Wu, X. Wang, S.C. Ward, A.I. Cederbaum, Chronic alcohol-induced
liver injury and oxidant stress are decreased in cytochrome P4502E1
knockout mice and restored in humanized cytochrome P4502E1 knock-in
mice, Free Radical Biology and Medicine 49 (9) (2010) 1406–1416. http://dx.
doi.org/10.1016/j.freeradbiomed.2010.07.026 20692331.
[86] W.E. Evans, M.V. Relling, Pharmacogenomics: translating functional geno-
mics into rational therapeutics, Science 286 (5439) (1999) 487–491. http:
//dx.doi.org/10.1126/science.286.5439.487 10521338.
[87] J. Dudley, K. Karczewski, Exploring Personal Genomics, Oxford University
Press, Oxford, 2013.
[88] M. Ingelman-Sundberg, S.C. Sim, Pharmacogenetic biomarkers as tools for
improved drug therapy; emphasis on the cytochrome P450 system, Bio-
chemical and Biophysical Research Communications 396 (1) (2010) 90–94.
http://dx.doi.org/10.1016/j.bbrc.2010.02.162 20494117.
[89] S.C. Preissner, M.F. Hoffmann, R. Preissner, M. Dunkel, A. Gewiess,
S. Preissner, Polymorphic cytochrome P450 enzymes (CYPs) and their role in
personalized therapy, PLOS One 8 (2013) e82562. http://dx.doi.org/10.1371/
journal.pone.0082562 24340040.
[90] U.M. Zanger, J. Fischer, S. Raimundo, T. Stüven, B.O. Evert, M. Schwab,
M. Eichelbaum, Comprehensive analysis of the genetic factors determining
expression and function of hepatic CYP2D6, Pharmacogenetics 11 (2001)
573–585.
[91] M. Wadelius, M. Pirmohamed, Pharmacogenetics of warfarin: current status
and future challenges, Pharmacogenomics Journal 7 (2007) 99–111. http:
//dx.doi.org/10.1038/sj.tpj.6500417 16983400.
[92] H. Schelleman, N.A. Limdi, S.E. Kimmel, Ethnic differences in warfarin
maintenance dose requirement and its relationship with genetics, Pharma-
cogenomics 9 (2008) 1331–1346. http://dx.doi.org/10.2217/
14622416.9.9.1331 18781859.
[93] H. Nakamura, J. Uetrecht, A.E. Cribb, M.A. Miller, N. Zahid, J. Hill, P.D. Josephy,
D.M. Grant, S.P. Spielberg, In vitro formation, disposition and toxicity of
N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole
toxicity, Journal of Pharmacology and Experimental Therapeutics 274 (3)
(1995) 1099–1104.
[94] J. de Leon, AmpliChip CYP450 test: personalized medicine has arrived in
psychiatry, Expert Review of Molecular Diagnostics 6 (2006) 277–286. http:
//dx.doi.org/10.1586/14737159.6.3.277 16706732.
[95] M.C. Rebsamen, J. Desmeules, Y. Daali, A. Chiappe, A. Diemand, C. Rey,
J. Chabert, P. Dayer, D. Hochstrasser, M.F. Rossier, The AmpliChipCYP450 test:
cytochrome P450 2D6 genotype assessment and phenotype prediction,
Pharmacogenomics Journal 9 (2009) 34–41. http://dx.doi.org/10.1038/
tpj.2008.7 18591960.
[96] J. de Leon, M.T. Susce, M. Johnson, M. Hardin, L. Maw, A. Shao, A.C. Allen,
F.A. Chiafari, G. Hillman, D.M. Nikoloff, DNA microarray technology in the
clinical environment: the Ampli Chip CYP450 test for CYP2D6 and CYP2C19
genotyping, CNS Spectrums 14 (2009) 19–34.
[97] F.P. Guengerich, Mechanisms of drug toxicity and relevance to pharmaceu-
tical development, Drug Metabolism and Pharmacokinetics 26 (1) (2011)
3–14. http://dx.doi.org/10.2133/dmpk.DMPK-10-RV-062 20978361.
[98] F.P. Guengerich, Q. Cheng, Orphans in the human cytochrome P450 super-
family: approaches to discovering functions and relevance in pharmacology,
Pharmacological Reviews 63 (3) (2011) 684–699. http://dx.doi.org/10.1124/
pr.110.003525 21737533.
[99] E.M. Gillam, Extending the capabilities of nature's most versatile catalysts:
directed evolution of mammalian xenobiotic-metabolizing P450s, Archives
of Biochemistry and Biophysics 464 (2) (2007) 176–186. http://dx.doi.org/
10.1016/j.abb.2007.04.033 17537393.
[100] E.M. Gillam, M.A. Hayes, The evolution of cytochrome P450 enzymes as
biocatalysts in drug discovery and development, Current Topics in Medicinal
Chemistry 13 (18) (2013) 2254–2280. http://dx.doi.org/10.2174/
15680266113136660158 24047135.
[101] R.B. Palakodety, L.A. Clejan, G. Krikun, D.E. Feierman, A.I. Cederbaum, Char-
acterization and identiﬁcation of a pyrazole-inducible form of cytochrome
P-450, Journal of Biological Chemistry 263 (2) (1988) 878–884.
